ClinicalTrials.gg
Not yet recruitingNCT06473948Updated Jun 25, 2024

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

A Phase 1 interventional study of JMKX001899 and JMKX001899 in Solid Tumor, Adult, sponsored by Jemincare. Not yet recruiting. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Jemincare · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers

Read the detailed description

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of JMKX001899 Administered as a Tablet Formulation Under Fed Conditions in Healthy Subjects

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

Jemincare is the lead sponsor of 37 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy, adult, male or female 18-45 years of age, inclusive.
  2. (BMI) between 19 and 28 kg/m2 (inclusive) and weight at least 50 kg.
  3. Participant must sign an form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of diseases including, but not limited to, gastrointestinal, renal, liver, neurological, hematological, endocrine, neoplastic, pulmonary, immune, psychiatric, or cardiovascular and cerebrovascular diseases, epilepsy, bipolar disorder/mania, intraocular hypertension, or acute angle-closure glaucoma.
  2. Female subjects with a positive pregnancy test or lactating.
  3. Positive results at screening for (HIV), surface antigen (HBsAg), virus (HCV) or Treponema pallidum(TP-Ab)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
27 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Participants will receive JMKX001899 500 once on Day 1

    Drug: JMKX001899 · Drug: Placebo

  • Experimental
    Cohort 2

    Participants will receive JMKX001899 750 once on Day 1

    Drug: JMKX001899 · Drug: Placebo

  • Experimental
    Cohort 3

    Participants will receive JMKX001899 1000 once on Day 1

    Drug: JMKX001899 · Drug: Placebo

Interventions

  • Participants will receive JMKX001899 500mg tablet, orally once on Day 1

  • Participants will receive JMKX001899 750mg tablet, orally once on Day 1

  • Participants will receive JMKX001899 1000mg tablet, orally once on Day 1

  • DrugPlacebo

    Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1

06

What researchers measure

Primary outcomes

  1. To evaluate the effect of a single dose of JMKX001899 on the change in time-matched QTc intervals compared with placebo

    QTc interval was measured by electrocardiograms to evaluate the potential effect of JMKX001899 plasma concentrations on the QTc interval using linear mixed-effect exposure-response modeling, including the predicted ddQTc at Cmax values corresponding to exposure levels

    Time frame: 48 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2024; primary completion for Sep 2024, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 19, 2024
First posted
Jun 25, 2024
StartEst.
Jul 10, 2024
Primary completionEst.
Sep 24, 2024
CompletionEst.
Feb 27, 2025
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06473948
Lead sponsor
Jemincare
Responsible party
Sponsor
First posted
Jun 25, 2024
Start date
Jul 10, 2024 (estimated)
Primary completion
Sep 24, 2024 (estimated)
Completion
Feb 27, 2025 (estimated)
Last update
Jun 25, 2024

Study contacts

WEIXIA LI
Contact
liweixia@jemincare.com
15000279084 ext. +86

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KRAS G12C Inhibitor JMKX001899

Start the discussion